Literature DB >> 21298632

Prenatal treatment with glucocorticoids sensitizes the hpa axis response to stress among full-term infants.

Elysia Poggi Davis1, Feizal Waffarn, Curt A Sandman.   

Abstract

The objective of this study was to determine the consequences for HPA axis functioning among healthy full-term newborns of prenatal treatment with the synthetic glucocorticoid (GC), betamethasone, which is the routine treatment for threatened preterm delivery. Ninety full-term infants were recruited into two study groups (30 betamethasone treated; 60 comparison group matched for GA at birth and sex). The cortisol and behavioral response to the painful stress of a heel-stick blood draw was assessed 24 hr after birth. Full-term infants exposed to prenatal betamethasone displayed a larger cortisol response to the heel-stick procedure, despite no differences in baseline levels. Further, within the recommended window of betamethasone administration (24-34 gestational weeks), infants exposed to betamethasone earlier in gestation displayed the largest cortisol response to the heel-stick. These data add to accumulating evidence that prenatal exposure to elevated GCs programs the development of the HPA axis.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21298632     DOI: 10.1002/dev.20510

Source DB:  PubMed          Journal:  Dev Psychobiol        ISSN: 0012-1630            Impact factor:   3.038


  37 in total

1.  Antenatal glucocorticoid treatment is associated with diurnal cortisol regulation in term-born children.

Authors:  M N Edelmann; C A Sandman; L M Glynn; D A Wing; E P Davis
Journal:  Psychoneuroendocrinology       Date:  2016-06-23       Impact factor: 4.905

2.  Single course of antenatal steroids did not alter cortisol in preterm infants up to 18 months.

Authors:  Ayala Gover; Susanne Brummelte; Anne R Synnes; Steven P Miller; Rollin Brant; Joanne Weinberg; Ruth E Grunau
Journal:  Acta Paediatr       Date:  2012-02-21       Impact factor: 2.299

Review 3.  Exposure to prenatal psychobiological stress exerts programming influences on the mother and her fetus.

Authors:  Curt A Sandman; Elysia P Davis; Claudia Buss; Laura M Glynn
Journal:  Neuroendocrinology       Date:  2011-04-15       Impact factor: 4.914

4.  Prenatal psychobiological predictors of anxiety risk in preadolescent children.

Authors:  Elysia Poggi Davis; Curt A Sandman
Journal:  Psychoneuroendocrinology       Date:  2012-01-20       Impact factor: 4.905

Review 5.  Glucocorticoids and fetal programming part 1: Outcomes.

Authors:  Vasilis G Moisiadis; Stephen G Matthews
Journal:  Nat Rev Endocrinol       Date:  2014-05-27       Impact factor: 43.330

Review 6.  Gestational restraint stress and the developing dopaminergic system: an overview.

Authors:  Carlos J Baier; María R Katunar; Ezequiela Adrover; María Eugenia Pallarés; Marta C Antonelli
Journal:  Neurotox Res       Date:  2012-01-04       Impact factor: 3.911

7.  Dexamethasone Induces Cardiomyocyte Terminal Differentiation via Epigenetic Repression of Cyclin D2 Gene.

Authors:  Maresha S Gay; Chiranjib Dasgupta; Yong Li; Angela Kanna; Lubo Zhang
Journal:  J Pharmacol Exp Ther       Date:  2016-06-14       Impact factor: 4.030

8.  Prenatal Maternal Cortisol Has Sex-Specific Associations with Child Brain Network Properties.

Authors:  Dae-Jin Kim; Elysia Poggi Davis; Curt A Sandman; Olaf Sporns; Brian F O'Donnell; Claudia Buss; William P Hetrick
Journal:  Cereb Cortex       Date:  2017-11-01       Impact factor: 5.357

Review 9.  Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations.

Authors:  Feizal Waffarn; Elysia Poggi Davis
Journal:  Am J Obstet Gynecol       Date:  2012-06-13       Impact factor: 8.661

10.  Fetal glucocorticoid exposure is associated with preadolescent brain development.

Authors:  Elysia Poggi Davis; Curt A Sandman; Claudia Buss; Deborah A Wing; Kevin Head
Journal:  Biol Psychiatry       Date:  2013-04-21       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.